Revenue: As of FY2026 Q2, the actual value is USD 129.86 M, beating the estimate of USD 118.85 M.

EPS: As of FY2026 Q2, the actual value is USD 0.11, beating the estimate of USD 0.0283.

EBIT: As of FY2026 Q2, the actual value is USD 17.56 M.

Second Quarter 2026 Financial Results

Segment Revenue

Arcutis Biotherapeutics, Inc. reported ZORYVE net product sales of $129.9 million for the second quarter of 2026, representing a 59% year-over-year growth compared to the second quarter of 2025 and a 23% sequential increase from the first quarter of 2026. Product revenues for the quarter ended June 30, 2026, were $129.9 million, compared to $81.5 million for the corresponding period in 2025. The breakdown of product revenue for Q2 2026 was: ZORYVE cream 0.3% at $35.3 million, ZORYVE cream 0.15% at $24.2 million, ZORYVE cream 0.05% at $2.9 million, and ZORYVE foam 0.3% at $67.4 million.

Operational Metrics

• Operating Costs:
  • Cost of sales for the second quarter of 2026 was $10.9 million, up from $7.5 million in the corresponding period of 2025.
  • Research and development (R&D) expenses were $20.4 million for Q2 2026, compared to $19.5 million for Q2 2025.
  • Selling, general, and administrative (SG&A) expenses increased to $82.1 million in Q2 2026 from $69.2 million in Q2 2025, primarily due to increased personnel costs and the expansion of the dermatology sales force.
• Net Income (Loss): Net income for the second quarter of 2026 was $15.0 million, compared to a net loss of - $15.9 million for the corresponding period in 2025.

Cash Flow

Arcutis Biotherapeutics, Inc. generated $12.6 million of cash flow from operating activities in the second quarter of 2026.

Cash, Cash Equivalents, Restricted Cash, and Marketable Securities

As of June 30, 2026, cash, cash equivalents, restricted cash, and marketable securities totaled $238.9 million, an increase from $221.3 million as of December 31, 2025.

Six Months Ended June 30, 2026 Financial Results

Segment Revenue

Total revenues for the six months ended June 30, 2026, were $235,259 thousand, compared to $147,350 thousand for the corresponding period in 2025. Product revenue, net, was $235,259 thousand for the six months ended June 30, 2026, versus $145,350 thousand for the same period in 2025.

Operational Metrics

• Operating Costs:
  • Cost of sales for the six months ended June 30, 2026, was $20,723 thousand, compared to $16,322 thousand in the prior year.
  • Research and development expenses were $50,982 thousand for the six months ended June 30, 2026, up from $36,996 thousand in 2025.
  • Selling, general, and administrative expenses increased to $156,214 thousand for the six months ended June 30, 2026, from $133,172 thousand in the corresponding period of 2025.
• Income (Loss) from Operations: Income from operations for the six months ended June 30, 2026, was $7,340 thousand, a significant improvement from a loss from operations of - $39,140 thousand in the same period of 2025.
• Net Income (Loss): Net income for the six months ended June 30, 2026, was $3,714 thousand, compared to a net loss of - $40,946 thousand for the corresponding period in 2025.

Key Personnel Compensation and Transition Payments

L. Todd Edwards, Chief Commercial Officer, is entitled to receive a transition payment of up to $175,000 upon his resignation, effective August 21, 2026. Robert Lisicki was appointed interim Executive Vice President and interim Chief Commercial Officer with an annual base salary of $555,000 and eligibility for a target annual performance bonus of 50% of his base salary, with a maximum achievement of 75%. He also received an option grant to purchase 145,000 shares of common stock and 55,000 restricted stock units, with specified severance benefits in the event of certain terminations during a change in control period.

Outlook / Guidance

Arcutis Biotherapeutics, Inc. raised its net product sales guidance for the full year 2026. The new guidance range is $525 million–$540 million, an increase from the previous guidance of $480 million–$495 million.